Vivesto AB, formerly Oasmia Pharmaceutical AB is a Swecen-based pharma company that develops new treatment options for patients suffering from difficult-to-treat cancer. The company has a growing portfolio of projects in the clinical phase focused on advanced cancer. Apealea (paclitaxel micellar) is being developed for patients with ovarian cancer through a partnership with Elevar Therapeutics, Inc. Other development programs include Cantrixil, a clinical program in advanced ovarian cancer, and docetaxel micellar, which is being developed for widespread prostate cancer. Vivesto's patented technology platform is developed to improve the water solubility, efficacy and safety of drugs.

Employees

Sector

Pharmaceuticals

More about the company

Market Cap	98.76M 10.35M 8.98M 8.38M 7.7M 14.55M 984M 14.71M 38.61M 492M 38.86M 38M 1.63B	P/E 2026 *	-2.92x	P/E 2027 *	-2.13x
Enterprise Value	90.76M 9.51M 8.26M 7.7M 7.07M 13.37M 904M 13.52M 35.48M 452M 35.71M 34.93M 1.5B	EV / Sales 2026 *	-	EV / Sales 2027 *	-
Free-Float	56.4%	Yield 2026 *	-	Yield 2027 *	-

07-07	Vivesto chairman Peter Zonabend increases his shareholding	FW
07-01	Vivesto Completes Enrollment in Cat Study of Paccal Vet	FW
07-01	Vivesto Completes Recruitment in Paccal Vet Dose-Finding Study in Cats and Determines Maximum Tolerated Dose	CI
06-26	Vivesto Completes Enrollment in Canine Study	FW
06-26	Vivesto Completes Recruitment in Paccal Vet Dog Pilot Study	CI
06-16	Vivesto AB Reports Positive Results From Intravenous Cantrixil Pharmacokinetic And Toxicology Study	CI
06-16	Vivesto reports positive results for intravenous Cantrixil	FW
06-05	Sweden's Vivesto Names New Finance Chief	MT
06-05	Vivesto appoints Björn Svanström as new CFO	FW
06-04	Vivesto AB Announces Chief Financial Officer Changes	CI
05-26	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
05-20	Vivesto trades on Nasdaq Stockholm today following 1:100 reverse stock split	FW
05-20	Calendar Wednesday May 20	FW

05-26	DNB Carnegie adjusts Vivesto fair value following reverse stock split	FW
11-21	DNB Carnegie Lowers Target Value for Vivesto Following Rights Issue Announcement	FW
25-08-13	DNB Carnegie Lowers Target Value for Vivesto as Costs Expected to Remain Steady	FW
24-07-09	Paccal Vet analysis could raise the temperature for Vivesto - Penser	FW
22-12-30	Orrön Energy the year's best and Isofol Medical the year's worst share on Nasdaq Stockholm	FW

07-01	Vivesto: Cat study enrolment completed, results expected in Q4	AQ
07-01	Vivesto completes recruitment in Paccal Vet study in cats and determines maximum tolerated dose	AQ
06-26	Vivesto: Paccal Vet top-line results expected in Q3	AQ
06-26	Vivesto completes recruitment in Paccal Vet dog pilot study – topline results expected Q3 2026	AQ
06-16	Vivesto: Positive data for Cantrixil	AQ

20-03-25	Oasmia Pharmaceutical AB (publ) : un partenariat stratégique pour la distribution d'Apealea
20-01-30	Oasmia Pharmaceutical AB (publ) : Apealea arrive sur les marchés scandinaves

Vivesto AB Stock OTC Markets

Stocks

OASMY

US67421W1099

Pharmaceuticals

Valuation: Vivesto AB

Chart: Vivesto AB

Latest news : Vivesto AB

Last Transcript: Vivesto AB

Analysts' recommendations: Vivesto AB

Press Releases: Vivesto AB

News in other languages: Vivesto AB

Managers and Directors: Vivesto AB

Other Pharmaceuticals

Financials

Company Profile

Manager	Title	Age	Since
Erik Kinnman CEO	Chief Executive Officer	68	2023-01-22
Björn Svanström DFI	Director of Finance/CFO	55	2026-06-30
Teresa Fernandez Zafra CTO	Chief Tech/Sci/R&D Officer	39	2022-12-31

Director	Title	Age	Since
Isak Peter Zonabend CHM	Chairman	46	2022-05-24
Hege Hellstrom BRD	Director/Board Member	61	2019-09-25
Pål Ryfors BRD	Director/Board Member	43	2022-05-24

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
VIVESTO AB	-.--%	-99.00%	-	-	10.35M
ELI LILLY AND COMPANY	+2.90%	-5.34%	+49.55%	+152.26%	995B
JOHNSON & JOHNSON	+1.17%	-3.08%	+50.73%	+48.68%	614B
ABBVIE INC.	+1.10%	-6.44%	+24.07%	+63.86%	431B
ROCHE HOLDING AG	+1.96%	+0.83%	+42.80%	+37.70%	353B
NOVARTIS AG	-0.11%	-4.07%	+30.37%	+38.52%	293B
ASTRAZENECA PLC	+2.52%	-8.36%	+7.27%	+10.56%	245B
AMGEN INC.	+4.50%	+4.41%	+34.88%	+60.02%	210B
NOVO NORDISK A/S	-4.32%	-12.94%	-3.79%	-46.07%	210B
GILEAD SCIENCES, INC.	-3.95%	-1.85%	+15.84%	+61.49%	168B
Average	+0.63%	-5.02%	+27.97%	+47.45%	390.92B
Weighted average by Cap.	+1.38%	-5.89%	+35.76%	+70.88%

	2026 *	2027 *
Net sales	-	-
Net income	-31M -3.25M -2.82M -2.63M -2.42M -4.57M -309M -4.62M -12.12M -154M -12.2M -11.93M -512M	-46M -4.82M -4.18M -3.9M -3.58M -6.78M -458M -6.85M -17.98M -229M -18.1M -17.7M -759M
Net Debt	-8M -838K -728K -679K -623K -1.18M -79.73M -1.19M -3.13M -39.86M -3.15M -3.08M -132M	-10M -1.05M -910K -848K -779K -1.47M -99.66M -1.49M -3.91M -49.82M -3.93M -3.85M -165M